Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Biotech Industry Analysis

UpdatedFeb 18, 2026
DataAggregated Company Financials
Companies5
  • 7D-0.8%
  • 3M-5.5%
  • 1Y-0.8%
  • YTD-4.9%

Over the last 7 days, the Biotech industry has dropped 1.7%, driven by declines from every company within the industry. Over the last year, the industry has been flat overall. As for the next few years, earnings are forecast to decline by 6.2% per annum.

Industry Valuation and Performance

Has the Danish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 18 Feb 2026DKK 163.2bDKK 40.4bDKK 18.9b6.1x8.6x4x
Fri, 16 Jan 2026DKK 178.1bDKK 40.8bDKK 19.1b6.4x9.3x4.4x
Sun, 14 Dec 2025DKK 174.1bDKK 40.5bDKK 19.0b6x9.2x4.3x
Tue, 11 Nov 2025DKK 161.5bDKK 40.5bDKK 18.3b10.4x8.8x4x
Thu, 09 Oct 2025DKK 183.9bDKK 39.0bDKK 16.8b12.7x10.9x4.7x
Sat, 06 Sep 2025DKK 158.5bDKK 38.8bDKK 16.8b12.3x9.5x4.1x
Mon, 04 Aug 2025DKK 127.5bDKK 27.2bDKK 7.4b12.7x17.2x4.7x
Wed, 02 Jul 2025DKK 120.0bDKK 26.8bDKK 7.3b10.6x16.5x4.5x
Fri, 30 May 2025DKK 131.2bDKK 27.5bDKK 7.5b10.8x17.4x4.8x
Sun, 27 Apr 2025DKK 126.3bDKK 27.3bDKK 7.7b11.4x16.4x4.6x
Tue, 25 Mar 2025DKK 136.9bDKK 27.3bDKK 7.7b11.7x17.8x5x
Thu, 20 Feb 2025DKK 167.6bDKK 27.7bDKK 7.8b12.4x21.4x6x
Sat, 18 Jan 2025DKK 162.4bDKK 26.0bDKK 4.7b17.1x34.6x6.2x
Mon, 16 Dec 2024DKK 162.7bDKK 26.0bDKK 4.7b16.6x34.7x6.3x
Wed, 13 Nov 2024DKK 176.0bDKK 26.0bDKK 4.3b22.1x41x6.8x
Fri, 11 Oct 2024DKK 174.9bDKK 25.5bDKK 5.5b20.9x32x6.9x
Sun, 08 Sep 2024DKK 196.3bDKK 25.5bDKK 5.5b23.8x35.9x7.7x
Tue, 06 Aug 2024DKK 185.6bDKK 24.8bDKK 5.6b17.4x33x7.5x
Thu, 04 Jul 2024DKK 188.1bDKK 24.8bDKK 5.6b17x33.4x7.6x
Sat, 01 Jun 2024DKK 179.8bDKK 24.8bDKK 5.6b18.7x31.9x7.2x
Mon, 29 Apr 2024DKK 177.6bDKK 23.9bDKK 5.0b18.5x35.2x7.4x
Wed, 27 Mar 2024DKK 194.7bDKK 23.9bDKK 5.0b20x38.7x8.1x
Fri, 23 Feb 2024DKK 174.1bDKK 22.8bDKK 4.2b24.4x41.3x7.6x
Sun, 21 Jan 2024DKK 170.6bDKK 23.3bDKK 4.2b23.7x41x7.3x
Tue, 19 Dec 2023DKK 172.6bDKK 23.3bDKK 4.2b25.4x41.5x7.4x
Thu, 16 Nov 2023DKK 174.7bDKK 22.9bDKK 4.5b22.3x38.7x7.6x
Sat, 14 Oct 2023DKK 177.8bDKK 22.0bDKK 4.7b20.6x37.5x8.1x
Mon, 11 Sep 2023DKK 199.3bDKK 22.0bDKK 4.7b23.1x42.2x9x
Wed, 09 Aug 2023DKK 193.3bDKK 20.6bDKK 3.9b37.9x50x9.4x
Fri, 07 Jul 2023DKK 198.4bDKK 19.5bDKK 4.4b39x45x10.1x
Sun, 04 Jun 2023DKK 208.1bDKK 19.5bDKK 4.4b41.9x47.2x10.6x
Tue, 02 May 2023DKK 209.6bDKK 17.9bDKK 4.1b33x51.2x11.7x
Thu, 30 Mar 2023DKK 198.0bDKK 17.9bDKK 3.5b30.6x55.8x11.1x
Sat, 25 Feb 2023DKK 203.6bDKK 17.3bDKK 3.1b31.5x64.8x11.7x
Price to Earnings Ratio

64.8x


Total Market Cap: DKK 203.6bTotal Earnings: DKK 3.1bTotal Revenue: DKK 17.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Biotech Industry Price to Earnings3Y Average 31.4x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 8.5x which is lower than its 3-year average PE of 31.5x.
  • The 3-year average PS ratio of 7.1x is higher than the industry's current PS ratio of 4.0x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have grown 79% per year over the last three years.
  • Revenues for these companies have grown 40% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare industry?

DK Market-2.39%
Healthcare-1.42%
Biotech-0.81%
Biotech-0.81%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GMAB GenmabDKK 1.95k0.8%
+DKK 954.8m		26.9%PE12x

Latest News

GMAB
DKK 1,953.50
Genmab
7D
0.8%
1Y
26.9%

GMAB: 2026 Pipeline Readouts And AI Use Will Drive Outlook

Analysts have made a small trim to their blended DKK price target on Genmab, with the model now pointing to roughly DKK 2,182. This reflects updated assumptions around slightly higher discount rates, a modestly different margin outlook and a lower future P/E multiple after recent coverage resets and target hikes from banks like Morgan Stanley, Deutsche Bank and Barclays.
BAVA
DKK 193.75
Bavarian Nordic
7D
-0.6%
1Y
10.1%
BIOPOR
DKK 0.99
BioPorto
7D
-0.3%
1Y
-33.7%
ZEAL
DKK 388.00
Zealand Pharma
7D
-7.4%
1Y
-50.5%

ZEAL: Metabolic Collaboration Will Drive Future Upside As Profitability Assumptions Improve

Analysts have trimmed their price target for Zealand Pharma from €745.93 to €735.27, reflecting updated assumptions around the discount rate, revenue growth, profit margin and future P/E that modestly adjust their overall valuation framework. What's in the News Zealand Pharma and OTR Therapeutics entered a multi program collaboration and license agreement focused on discovering and developing novel therapeutics for metabolic diseases, combining Zealand Pharma's obesity and metabolic health expertise with OTR Therapeutics' R&D platform (Key Developments).
STRAP
DKK 562.00
Strategic Partners
7D
-6.3%
1Y
-32.3%